Acalabrutinib

Common brands: Calquence, Allopurinol, Aloprim, Rituxan, Vitamin D

Top reporter: Astrazeneca Pharmaceuticals Lp

Kinase Inhibitor [EPC]CD20-directed Cytolytic Antibody [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Corticosteroid [EPC]Xanthine Oxidase Inhibitor [EPC]
11,444
Total Reports
10,195
Serious Reports
2,493
Death Reports
30
Reported Reactions
Death Report Ratio: High (21.78%)

Patient Demographics

Male
5,992
Female
3,516

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Acalabrutinib.

# Reaction Reports % of Total
1 DEATH 2,018
20.4%
2 FATIGUE 647
6.5%
3 HEADACHE 604
6.1%
4 PRODUCT DOSE OMISSION ISSUE 429
4.3%
5 DIARRHOEA 393
4.0%
6 FALL 339
3.4%
7 DYSPNOEA 315
3.2%
8 CONTUSION 308
3.1%
9 MALIGNANT NEOPLASM PROGRESSION 306
3.1%
10 PNEUMONIA 300
3.0%
11 ASTHENIA 292
2.9%
12 PAIN 270
2.7%
13 ATRIAL FIBRILLATION 269
2.7%
14 OFF LABEL USE 261
2.6%
15 NAUSEA 248
2.5%
16 ARTHRALGIA 243
2.5%
17 DIZZINESS 241
2.4%
18 COVID-19 240
2.4%
19 RASH 234
2.4%
20 PYREXIA 221
2.2%
21 ANAEMIA 216
2.2%
22 DRUG INEFFECTIVE 186
1.9%
23 MYALGIA 175
1.8%
24 WHITE BLOOD CELL COUNT INCREASED 175
1.8%
25 PERIPHERAL SWELLING 170
1.7%
26 HAEMORRHAGE 167
1.7%
27 LYMPHADENOPATHY 166
1.7%
28 PLATELET COUNT DECREASED 165
1.7%
29 DISEASE PROGRESSION 155
1.6%
30 HAEMOGLOBIN DECREASED 154
1.6%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.